Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Incyte Corporation INCY

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:INCY)

Fundamentals Snapshot (NDAQ:INCY)

Opinion & Analysis (NDAQ:INCY)

Immuno-Oncology candidate yields 'impressive' early clinical results

Streetwise Reports December 7, 2017

3 Biotech ETFs Rally On Merger News

Benzinga.com  December 8, 2014

Stock picks that include a couple of Canadian miners

J.W. Cotton June 26, 2009

Bullboard Posts (NDAQ:INCY)

INCY / INCYTE corporation - A good Investment option

<< View Post To Watch Video >>
flyjeetu - May 26, 2021

Take a look at Theralase vtlt

They may hold the cure for bladder cancer as well as brain and lung cancer In clinical trial for bladder cancer looking very good .This...
goregil - February 12, 2019

Buy rating and $19 price

Piper Jaffray adds Incyte Corp. to its Alpha List, citing a positive data release on Incyte's lead JAK2 inhibitor at the European...
mart33 - April 8, 2008

news/ratings ta

NEW YORK, February 18 - Analysts at UBS maintain their "buy" rating on Incyte Corp  while reducing their estimates for the...
mart33 - March 24, 2008

Incyte Reports 47% UP ( INCY : Nasdaq)

10/17/00 - Incyte Reports 47% Year-to-year Increase in Third Quarter Revenue PALO ALTO, Calif., Oct. 17 /PRNewswire/ -- Incyte...
Nano2000 - October 18, 2000

Nice,in at 31.25,today reached up to 71

before settling at 47....GOOD NEWS:discovery of a gene related with diabetes type 2.
NeedaQuarterMill - December 22, 1999